Welcome to our dedicated page for NH news (Ticker: NH), a resource for investors and traders seeking the latest updates and insights on NH stock.
NantHealth (NH) delivers innovative healthcare solutions through its unique integration of advanced diagnostics and comprehensive data analytics. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's progress in precision medicine.
Access timely reports on clinical developments, technology partnerships, and operational milestones that shape NH's position in healthcare innovation. Our curated collection includes earnings announcements, regulatory filings, product launch details, and strategic collaborations within the medical technology sector.
Key areas of coverage feature NH's systems-based approach to treatment optimization, advancements in biometric data integration, and initiatives supporting value-based care models. Stay informed about developments impacting personalized healthcare delivery and diagnostic technology evolution.
Bookmark this page for streamlined access to verified NH updates. Check regularly for new insights into how the company continues bridging healthcare services with actionable data solutions.
NantHealth (NASDAQ: NH) has launched a new population health management product designed to aggregate disparate data for a holistic view of patient care. This solution aims to enhance workflow efficiency among providers, payers, and patients while reducing unnecessary costs. With the trend towards value-based care, the product enables better healthcare delivery by leveraging historical data and advanced analytics. According to the American Hospital Association, many providers are already engaging in alternative payment models, indicating the relevance of NantHealth's offering in current healthcare dynamics.
NantHealth, Inc. (NASDAQ-GS: NH) reported its Q4 and full-year 2020 financial results, demonstrating resilience amid COVID-19 challenges. Q4 net revenue was $18.6 million, matching Q4 2019, with a gross profit of $11.4 million (61% of revenue). SG&A expenses declined to $11.7 million, while R&D investments rose to $4.8 million. However, the net loss from continuing operations increased to $20.1 million ($0.18 per share), influenced by a noncash charge of $8.1 million. For the full year, total revenue was $73.2 million, down from $77.4 million in 2019, with a yearly net loss of $88.3 million ($0.80 per share).
NantHealth, Inc. (NASDAQ-GS: NH) will release its financial results for the fourth quarter and full year of 2020 on February 25, 2021, post-market. The company will conduct a conference call at 1:30 p.m. PT to discuss its performance. Interested parties can join the call by dialing relevant numbers or via an online broadcast at www.nanthealth.com. NantHealth offers enterprise solutions that enable businesses to transform complex data into actionable insights across various industries.
NantHealth announced a collaboration with Sesame, a healthcare platform, enabling providers to offer affordable care and potentially increasing revenue by 25% per visit. With nearly half of U.S. adults uninsured or underinsured, this partnership aims to enhance access to healthcare through direct-to-patient services. Providers using NantHealth's NaviNet platform can streamline administrative processes while accessing affordable care options. Sesame has raised over $23 million to support its model, focusing on simplifying healthcare for patients and enhancing practice revenue for providers.
NantHealth, Inc. (NASDAQ: NH) presented new findings at the San Antonio Breast Cancer Symposium regarding the adoption of trastuzumab biosimilars for HER2-positive breast cancer treatment. The study analyzed data from the Eviti Connect platform from June 2019 to October 2020, showing that biosimilar adoption has risen over time and is influenced by payer policies. The results indicate that these biosimilars can provide high-quality care while lowering costs. This suggests opportunities for payers to redirect providers towards biosimilars for significant societal savings.
NantHealth (NH) announced a study demonstrating the viability and significant clinical value of RNA sequencing in analyzing cancer patients' disease biology. Published in Nature's Scientific Reports, the study achieved an 81% sequencing success rate with 98% agreement between FFPE and fresh-frozen samples. This research promotes a deeper understanding of tumor drivers and aids in personalized treatment decisions. Insights from this method may enhance the identification of cancers of unknown primary and optimize immunotherapy treatments.
NantHealth, Inc. (NASDAQ-GS: NH) will report its 2020 third-quarter financial results on November 5, 2020, after market close. The management team will conduct a conference call at 1:30 p.m. PT (4:30 p.m. ET) to discuss the company's performance. Interested parties can join the call by dialing U.S./Canada: 844-309-3709 or international: 281-962-4864, with passcode 9966656. The call will also be streamed live on the NantHealth website.
NantHealth, Inc. (NASDAQ: NH) presented at the AACR Virtual Special Conference on Pancreatic Cancer on September 29-30, highlighting their research on deep-learning models to assess tumor and immune cell interactions. The study involved 82 pancreatic adenocarcinoma patients and revealed that image-based risk models significantly outperformed standard clinical assessments in predicting patient survival. Key findings include the independence of image-based features for prognosis and the need for larger studies to validate results. This research emphasizes advancements in digital pathology as essential for improving pancreatic cancer treatment.
